Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Moodys
AstraZeneca

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,173,037

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,173,037 protect, and when does it expire?

Patent 7,173,037 protects ADEMPAS and is included in one NDA.

This patent has forty-five patent family members in thirty-five countries.

Summary for Patent: 7,173,037
Title:Carbamate-substituted pyrazolopyridines
Abstract: The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.
Inventor(s): Alonso-Alija; Cristina (Haan, DE), Bischoff; Erwin (Wuppertal, DE), Munter; Klaus (Wulfrath, DE), Stasch; Johannes-Peter (Solingen, DE), Stahl; Elke (Gladbach, DE), Weigand; Stefan (Wuppertal, DE), Feurer; Achim (Wilhelmsfeld, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/513,869
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,173,037
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,173,037

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-001 Oct 8, 2013 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-002 Oct 8, 2013 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-003 Oct 8, 2013 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-004 Oct 8, 2013 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-005 Oct 8, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,173,037

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 20 570May 8, 2002
PCT Information
PCT FiledApril 25, 2003PCT Application Number:PCT/EP03/04304
PCT Publication Date:November 20, 2003PCT Publication Number: WO03/095451

International Family Members for US Patent 7,173,037

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039789   Start Trial
Austria 330957   Start Trial
Australia 2003233061   Start Trial
Brazil 0309855   Start Trial
Brazil PI0309855   Start Trial
Canada 2485143   Start Trial
China 1330649   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Express Scripts
Boehringer Ingelheim
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.